deutsch- Pancreatic elastase 1
- Tumor M2-PK EDTA plasma
- Tumor M2-PK colorectal cancer screening
- Antibodies
- Quick-Prep
- Brainostic
- Veterinary diagnostic
ScheBo® • Quick-Prep™
... the revolutionary stool sample extraction system for every laboratory!
PRODUCT INNOVATION!
ScheBo® • Biotech AG exclusively introduces the brand-new ScheBo® • Quick-Prep™ (for use in conjunction with the ScheBo® • Pancreatic Elastase 1 stool test and the ScheBo® • Tumor M2-PK™ ELISA stool test). The ScheBo® • Quick-PrepTM has been available since the beginning of October 2002.
These are the advantages of the ScheBo® • E1 Quick-Prep™:
- Save time and money: between 75% and 80% depending on current method
- Save on material cost: 20%
- Total saving per test: up to 53%
- Maximum precision: average c.v. for the complete test = 5%
- No additional equipment needed
- Machine compatible
- Hygienic execution, no unpleasant smell
- Enthusiastic customers and medical laboratory assistants
- Easy to perform using the ScheBo® • Quick-Prep™ -technology
A Decade of UK Success for Schebo Biotech
ScheBo® Biotech UK Limited, a leading provider of unique in-vitro diagnostic tests for the healthcare sector, has just celebrated its 10th Anniversary.
more...
more...
A superior alternative for PLT users: Faecal Pancreatic Elastase Test
Pfizer recommends this test in a letter it sent to pharmacists notifying them about the withdrawal of PLT.
more...
more...
Tumour M2-PK as a stool marker for colorectal cancer
Comparative analysis in a large sample of unselected older adults vs colorectal cancer patients.
more...
more...
Coeliac disease and pancreatic exocrine insufficiency
The data have shown that pancreatic insufficiency, demonstrated by low faecal pancreatic elastase-1 levels, is common in adult coeliac disease patients.
more...
more...
Colorectal cancer screening by non-invasive metabolic biomarker fecal tumor M2-PK
Fecal tumor M2-PK is an appropriately sensitve tool to pre-select those patients requiring colonoscopy for the further diagnostic confirmation or exclusion of colorectal cancer.
more...
more...